Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Watkin

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Current Therapeutic Research, Clinical and Experimental|March 29, 2014
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting dosesDavid L Dunner, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Clinical Trials (London, England)|November 11, 2005
The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVACraig H Mallinckrodt, Christopher J Kaiser, John G Watkin, et al.
Human Pathology|February 10, 2000
Invasive micropapillary carcinoma of the breast: a prognostic studyM Paterakos, W G Watkin, S M Edgerton, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?Maurizio Fava, Craig H Mallinckrodt, Michael J Detke, et al.
BMC Psychiatry|September 10, 2004
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsCraig H Mallinckrodt, Joel Raskin, Madelaine M Wohlreich, et al.
Journal of Affective Disorders|June 20, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patientsDonna E Stewart, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Journal of the American Chemical Society|June 13, 2002
A mechanistic study of the samarium(II)-mediated reduction of aryl nitro compounds to the corresponding crylamines. The crystal structures of [Sm[N(SiMe(3))(2)](2)(thf)](2)(mu(2)-O) and [(Me(3)Si)(2)N](2)Sm(thf)(mu-PhNNPh)Sm[N(SiMe(3))(2)](2)Erik D Brady, David L Clark, D Webster Keogh, et al.
Journal of the National Medical Association|April 1, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacyRahn K Bailey, Craig H Mallinckrodt, Madelaine M Wohlreich, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1977
Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acidJ A Walder, R H Zaugg, R S Iwaoka, et al.
The Journal of Clinical Psychiatry|July 18, 2006
Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trialsSusan G Kornstein, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Current Therapeutic Research, Clinical and Experimental|March 29, 2014
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting dosesDavid L Dunner, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Clinical Trials (London, England)|November 11, 2005
The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVACraig H Mallinckrodt, Christopher J Kaiser, John G Watkin, et al.
Human Pathology|February 10, 2000
Invasive micropapillary carcinoma of the breast: a prognostic studyM Paterakos, W G Watkin, S M Edgerton, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?Maurizio Fava, Craig H Mallinckrodt, Michael J Detke, et al.
BMC Psychiatry|September 10, 2004
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsCraig H Mallinckrodt, Joel Raskin, Madelaine M Wohlreich, et al.
Journal of Affective Disorders|June 20, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patientsDonna E Stewart, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Journal of the American Chemical Society|June 13, 2002
A mechanistic study of the samarium(II)-mediated reduction of aryl nitro compounds to the corresponding crylamines. The crystal structures of [Sm[N(SiMe(3))(2)](2)(thf)](2)(mu(2)-O) and [(Me(3)Si)(2)N](2)Sm(thf)(mu-PhNNPh)Sm[N(SiMe(3))(2)](2)Erik D Brady, David L Clark, D Webster Keogh, et al.
Journal of the National Medical Association|April 1, 2006
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacyRahn K Bailey, Craig H Mallinckrodt, Madelaine M Wohlreich, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1977
Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acidJ A Walder, R H Zaugg, R S Iwaoka, et al.
The Journal of Clinical Psychiatry|July 18, 2006
Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trialsSusan G Kornstein, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Pageof 5